Advances in the Use of Surgery and Multimodality Treatment for N2 Non-Small Cell Lung Cancer

Expert Review of Anticancer Therapy - United Kingdom
doi 10.1080/14737140.2017.1319766
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

P3.01-89 Upfront Surgery Versus Neoadjuvant Treatment Followed by Surgery in Pathologic N2 Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Surgery in Microscopically Pathological N2 Non-Small Cell Lung Cancer: The Size of Lymph Node Matters

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Advances in Immune Therapy for Non Small Cell Lung Cancer

Medical Diagnosis
2016English

P3.17-05 Multimodality Treatment for Superior Sulcus Non-Small-Cell Lung Carcinomas

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Demonstration of the Skip Metastasis Pathway for N2 Non–small Cell Lung Cancer

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2014English

Gefitinib for the Treatment of Non-Small-Cell Lung Cancer

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2010English

A Nomogram to Predict the Survival of Stage IIIA-N2 Non-Small Cell Lung Cancer After Surgery

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2018English

Tri-Modality Treatment in N2 Stage IIIa Non-Small Cell Lung Cancer: Proper Sequence Remains Unknown

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2018English

Trimodality Therapy in the Treatment of Stage III N2‐Positive Non‐Small Cell Lung Cancer: A National Cancer Database Analysis

Oncologist
Cancer ResearchMedicineOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy